Celloid has signed a Memorandum of Understanding (MOU) with YiPSCELL, a company specializing in the development of regenerative therapies based on induced pluripotent stem cells (iPSCs).

Through this partnership, the two companies will collaborate on developing organoid-based regenerative therapies, with a particular focus on treatments for cartilage and liver diseases. Their goal is to provide personalized treatment solutions in the field of advanced regenerative medicine by leveraging 3D cell culture automation technology.